Sriram Ryali
Disclosed holdings of Sriram Ryali as of 2026-02-20: 72K shares of Caribou Biosciences (CRBU), worth about $34K at the last close. From SEC Form 4 filings…
What Sriram Ryali reported holding
As of the latest filing on , Sriram Ryali reported holding 72,360 shares of Caribou Biosciences (CRBU), worth about $34K at the last close of $0 (Oct 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Caribou Biosciences CRBU | 72,360 | 72K direct | $0 | $34K | Feb 20, 2026 |
Is this Sriram Ryali’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Insider buying and selling since 2023
Sriram Ryali bought shares on the open market in 2023 and 2025 across 2 companies.
Sriram Ryali reported 2 open-market purchases and 0 sales since 2023; purchases in 2 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | 1×1 trade | — |
| 2023 | 1×1 trade | — |
Insider at 2 companies
- Caribou Biosciences CRBU2025 · 1 purchase, 0 sales
- Codexis CDXS2023 · 1 purchase, 0 sales
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
The companies behind these filings
- Caribou Biosciences CRBU
Sriram Ryali reported 1 open-market purchase and 0 sales here, 2025.
- Market value
- $49.7M
- Last close
- $0.464
- 12 months
- −82.4%
- Against the S&P 500
- −97.7 pts
- Net margin
- -1327.4%
- Revenue (last year)
- $11.2M
- Codexis CDXS
Sriram Ryali reported 1 open-market purchase and 0 sales here, 2023.
- Market value
- $145M
- Last close
- $1.32
- 12 months
- −50.2%
- Against the S&P 500
- −65.5 pts
- Net margin
- -62.5%
- Revenue (last year)
- $70.4M
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Trades disclosed
Latest trade
Largest trade
Companies
Every disclosed trade
Every trade this person has disclosed
Newest first, each one linked to the filing it came from.
Free account: get the written context of this page. Already a member? Sign in
What this page holds
- Every disclosed trade, newest first
- How purchases did after they were reported
- Companies and committees involved
- A link to every official filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Sriram Ryali's trades
Has Sriram Ryali bought shares on the open market?
Sriram Ryali bought shares on the open market in 2023 and 2025 across 2 companies.
When did Sriram Ryali last buy or sell shares?
In SEC filings since 2023: the latest open-market purchase is from 2025; no open-market sale is on record.
Which companies has Sriram Ryali traded as an insider?
2 companies: Caribou Biosciences (CRBU, 2025), Codexis (CDXS, 2023).